Gehen Sie mit der App Player FM offline!
The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect
Manage episode 447629670 series 10998
Educational Objectives
- Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer
- Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence
Faculty
Lauren Ledbetter, PharmD, BCOP
Clinical Pharmacy Specialist, Thoracic Medical Oncology
The James Cancer Hospital at The Ohio State University
Columbus, Ohio
Moderator
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
University of Kansas Cancer Center
Division of Hematologic Malignancies & Cellular Therapeutics
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.
This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.
1603 Episoden
Manage episode 447629670 series 10998
Educational Objectives
- Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer
- Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence
Faculty
Lauren Ledbetter, PharmD, BCOP
Clinical Pharmacy Specialist, Thoracic Medical Oncology
The James Cancer Hospital at The Ohio State University
Columbus, Ohio
Moderator
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
University of Kansas Cancer Center
Division of Hematologic Malignancies & Cellular Therapeutics
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.
This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.
1603 Episoden
Alle Folgen
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.